A Phase I/IIa trial of VTD-panobinostat treatment and panobinostat maintenance in relapsed and relapsed/refractory multiple myeloma patients

Trial Profile

A Phase I/IIa trial of VTD-panobinostat treatment and panobinostat maintenance in relapsed and relapsed/refractory multiple myeloma patients

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Panobinostat (Primary) ; Bortezomib; Dexamethasone; Thalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MUK six
  • Most Recent Events

    • 16 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 08 Dec 2015 Preliminary results of expansion phase II presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
    • 25 Jun 2015 Planned End Date changed from 1 Jan 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top